Alexander Vukasin, MD
Urology · Princeton, NJNPI 1659392546
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,800 of the $23,623 with a category attached, or 88.0%. Medtronic accounts for 89.3% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $21,337, more than ten times the $841 reported in 2019. Among urology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 102 payments — averaging $231.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$21K
- Procept Biorobotics Corporation$239
- Astellas Pharma US Inc$207
- AbbVie$206
- Teleflex LLC$166
- Johnson & Johnson$164
- plus $2K from 28 others
What the payments were for
- Consulting fees$20,80088%
- Food & beverage$2,76012%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 7 | $21,102 |
| Procept Biorobotics Corporation | 4 | $239 |
| Astellas Pharma US Inc | 14 | $207 |
| AbbVie(2 entities) | 7 | $206 |
| Teleflex LLC | 2 | $166 |
| Johnson & Johnson(2 entities) | 9 | $164 |
| EDAP Technomed Inc | 1 | $138 |
| Baxter Healthcare | 2 | $119 |
| Ambu Inc. | 3 | $108 |
| Olympus America Inc. | 2 | $106 |
| Laborie Medical Technologies Corp. | 2 | $102 |
| Boston Scientific | 3 | $90 |
| Endo Pharmaceuticals Inc. | 6 | $81 |
| Bayer | 4 | $77 |
| Telix Pharmaceuticals | 1 | $74 |
| 180 Medical, Inc. | 3 | $71 |
| Amgen | 4 | $58 |
| Tolmar Pharmaceuticals, Inc. | 4 | $56 |
| Neotract Inc. | 2 | $55 |
| Tolmar, Inc. | 3 | $55 |
| BK Medical Holding Company Inc. | 1 | $47 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $46 |
| Myovant Sciences Inc. | 3 | $44 |
| Dendreon Pharmaceuticals LLC | 2 | $37 |
| Ferring Pharmaceuticals Inc. | 2 | $30 |
| Coloplast | 2 | $26 |
| Endo USA, Inc. | 1 | $19 |
| Cook Medical LLC | 1 | $18 |
| Photocure Inc | 1 | $14 |
| Dentsply IH Inc. | 1 | $14 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $14 |
| Palette Life Sciences, Inc. | 1 | $14 |
| Metuchen Pharmaceuticals | 1 | $13 |
| Aytu Biopharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift System$138
- FOCAL ONE$138
- INTERSTIM$137
- BOTOX$125
- AquaBeam Robotic System$120
How this compares
$23,623 in reported general payments places this provider in the 90th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 98 | $81,321 |
| Tamsulosin Hcl | 750 | $17,356 |
| Methenamine Hippurate | 184 | $15,599 |
| GemtesaVibegron | 17 | $10,137 |
| Dutasteride | 236 | $8,184 |
| Silodosin | 66 | $8,183 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 200 | $7,162 |
| Testosterone | 20 | $5,011 |
| Tadalafil | 62 | $4,748 |
| Potassium Citrate ErPotassium Citrate | 38 | $4,220 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 14 | $4,050 |
| Finasteride | 196 | $3,776 |
| Solifenacin Succinate | 63 | $3,284 |
| Tolterodine Tartrate ErTolterodine Tartrate | 26 | $2,698 |
| Trospium Chloride | 73 | $2,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $207 | $81,32198 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 401 urology providers in New Jersey.
Other urology in Princeton
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
- Robert SimonCliffside Park$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.